Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.

摘要: Abstract Background Pemetrexed is a folate analog inhibitor for the treatment of non–small-cell lung cancer (NSCLC) and malignant pleural mesothelioma. Folic acid vitamin B12 supplementation before initiating pemetrexed necessary because high rates cytopenias without supplementation. However, timing has not been thoroughly investigated. Patients Methods This was single-center, retrospective study investigating patients receiving from January 1, 2012, to June 30, 2015, who received same-day versus ≥ 1 day pemetrexed. The objective evaluate safety outcomes in on same as (group A) versus B12 ≥ B) Results Two hundred eighty-one met inclusion criteria: 137 group A (same-day administration B12) 144 B (median time pemetrexed, 7 days; range, 1-42 days). Mean changes hematologic indices cycle (C) C2 or C3 did differ significantly between groups. There were no significant differences clinical events C1 requiring supportive care. difference noted delay [28/114 (24.6%) vs. 14/118 (11.9%) B, P = .0164]. In A, predictors baseline hemoglobin (mean 13.3 g/dL 12.4 g/dL, .0137) ANC 6 × 109/L 5 × 109/L, .0003). Conclusion Same-day safe practice NSCLC mesothelioma patients.